Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;6(10):562-76.
doi: 10.1038/nrendo.2010.147.

Genetic causes and treatment of isolated growth hormone deficiency-an update

Affiliations
Review

Genetic causes and treatment of isolated growth hormone deficiency-an update

Kyriaki S Alatzoglou et al. Nat Rev Endocrinol. 2010 Oct.

Abstract

Isolated growth hormone deficiency is the most common pituitary hormone deficiency and can result from congenital or acquired causes, although the majority of cases are idiopathic with no identifiable etiology. Known genes involved in the genetic etiology of isolated growth hormone deficiency include those that encode growth hormone (GH1), growth-hormone-releasing hormone receptor (GHRHR) and transcription factor SOX3. However, mutations are identified in a relatively small percentage of patients, which suggests that other, yet unidentified, genetic factors are involved. Among the known factors, heterozygous mutations in GH1 remain the most frequent cause of isolated growth hormone deficiency. The identification of mutations has clinical implications for the management of patients with this condition, as individuals with heterozygous GH1 mutations vary in phenotype and can, in some cases, develop additional pituitary hormone deficiencies. Lifelong follow-up of these patients is, therefore, recommended. Further studies in the genetic etiology of isolated growth hormone deficiency will help to elucidate mechanisms implicated in the control of growth and may influence future treatment options. Advances in pharmacogenomics will also optimize the treatment of isolated growth hormone deficiency and other conditions associated with short stature, for which recombinant human growth hormone is a licensed therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Trends Endocrinol Metab. 2007 May-Jun;18(4):134-41 - PubMed
    1. J Clin Endocrinol Metab. 2001 Jan;86(1):273-9 - PubMed
    1. J Clin Endocrinol Metab. 2005 Dec;90(12):6431-40 - PubMed
    1. Pediatr Res. 1998 Jan;43(1):105-10 - PubMed
    1. BMJ. 2002 Jul 13;325(7355):70 - PubMed

MeSH terms

Substances